UroGen Pharma Ltd. (URGN)

Market Cap	583.28M
Revenue (ttm)	85.01M
Net Income (ttm)	-113.58M
Shares Out	42.11M
EPS (ttm)	-3.27
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	980,043
Open	13.27
Previous Close	13.10
Day's Range	13.24 - 14.57
52-Week Range	10.60 - 20.70
Beta	1.12
Analysts	Strong Buy
Price Target	48.38 (+249.31%)
Earnings Date	Nov 12, 2024

About URGN

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company’s lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate ris...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 4, 2017
• Employees: 201
• Stock Exchange: NASDAQ
• Ticker Symbol: URGN
• Website: https://www.urogen.com

Financial Performance

In 2023, UroGen Pharma's revenue was $82.71 million, an increase of 28.52% compared to the previous year's $64.36 million. Losses were -$102.24 million, -6.87% less than in 2022.

Analyst Forecast

According to 4 analysts, the average rating for URGN stock is "Strong Buy." The 12-month stock price forecast is $48.38, which is an increase of 249.31% from the latest price.

Price Target

$48.38

(249.31% upside)

Analyst Consensus: Strong Buy